Why You Should Know About Heart Bioregulators (Chelohart)
Cardiovascular science is one of the most extensively researched areas in medicine.
Within it, a relatively niche but scientifically distinct field has developed over several decades: the study of heart bioregulators.
Heart bioregulators are short peptide complexes derived from cardiac tissue and are studied for their role in cardiac gene expression and cardiomyocyte (heart muscle cell) biology.
The research in this area is most closely associated with Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology, whose work on tissue-specific peptide bioregulators spans over four decades.
Chelohart, the A-14 heart peptide complex, is one of the most studied compounds to emerge from this research tradition.
What Are Bioregulators and Why Are They Different To Peptides?
The term bioregulator refers to a class of short peptides, typically two to four amino acids in length, that are proposed to regulate gene expression in a tissue-specific manner.
The Khavinson bioregulator model is built on the principle that these short peptide sequences interact directly with chromatin (the complex of DNA and proteins that makes up chromosomes) and influence the transcription of genes relevant to the tissue from which they are derived.
This distinguishes bioregulators from most other research peptides in an important way.
Compounds such as growth hormone secretagogues or neuroprotective peptides typically work through receptor-mediated signalling pathways, where the peptide binds to a receptor on the cell surface and triggers a downstream biological response.
Bioregulators, within the Khavinson model, are proposed to work at the level of gene regulation itself, entering the cell nucleus and modulating which genes are expressed.
Each bioregulator in the Khavinson system is derived from a specific organ or tissue and is studied for its effects on that tissue’s biology.
Heart bioregulators are derived from cardiac tissue and studied specifically in relation to cardiomyocyte function and cardiac gene expression.
The Khavinson Research Tradition and Its Scientific Context
Professor Vladimir Khavinson began developing the bioregulator research programme in the 1970s, initially within the Soviet military medical system.
The original point of motivation was to develop compounds that could protect soldiers from radiation exposure and physiological stress under extreme conditions.
The research quickly expanded into broader questions of cellular ageing and organ-specific tissue regulation.
The bioregulator compounds developed from this work are known as Cytomaxes in their natural extract form.
Cytomaxes are derived from the organs of young animals using a patented extraction process.
Each Cytomax is studied for tissue-specific effects, with the hypothesis that peptides derived from a given organ type will selectively regulate gene expression in the corresponding human tissue.
A 2021 systematic review by Khavinson et al., published in Molecules, examined the evidence base for peptide regulation of gene expression across the bioregulator research programme. The review summarised decades of preclinical and early clinical findings supporting the tissue-specific gene-regulatory model that underpins the entire Khavinson bioregulator system.
What Is Chelohart and What Is It Studied For?
Chelohart is the A-14 heart peptide complex within the Khavinson Cytomax range.
It is derived from cardiac muscle tissue and is studied specifically in relation to cardiomyocyte biology and cardiac gene expression.
Cardiomyocytes are the specialised muscle cells that make up the myocardium (the muscular wall of the heart). Unlike most muscle cells in the body, cardiomyocytes have very limited capacity for self-renewal.
Research into compounds that may influence cardiomyocyte gene expression is therefore of particular interest in the context of cardiac ageing and the biological changes that accompany it.
Within the Khavinson bioregulator model, Chelohart is proposed to interact with chromatin in cardiomyocytes and modulate the expression of genes involved in cardiac muscle function, energy metabolism, and cellular maintenance.
Research has examined Chelohart in relation to the following biological areas:
- Cardiomyocyte gene expression regulation. Research into Chelohart’s proposed interactions with chromatin has examined its relationship to the transcription of genes involved in cardiac muscle cell structure and function, including those associated with contractile protein synthesis.
- Cardiac energy metabolism. Studies have examined the relationship between Chelohart and metabolic pathways within cardiomyocytes, with interest in how bioregulator peptides may interact with the energy production processes on which cardiac muscle function depends.
- Oxidative stress modulation in cardiac tissue. Research has investigated the relationship between Chelohart and oxidative stress markers (indicators of cellular damage caused by unstable reactive molecules) within cardiac tissue, an area of particular relevance given the high metabolic demands placed on heart muscle cells.
- Age-related changes in cardiomyocyte biology. A significant portion of Chelohart research sits within the broader context of cardiovascular ageing, examining how bioregulator peptides interact with the biological changes in cardiac tissue that accompany ageing.
How Is Chelohart Is Administered?
Chelohart is administered orally in capsule form.
Each capsule contains 10mg of the A-14 heart peptide complex.
Oral administration is the standard format for Cytomax bioregulators, which are distinct from many other research peptides in this respect.
The short chain length of the peptide sequences involved (typically two to four amino acids) is proposed to allow absorption through the gastrointestinal tract without the degradation that affects larger peptide molecules when taken orally.
Curious About Peptide Bioregulator Research?
The field of peptide bioregulators represents a distinct and historically significant area of peptide science.
Understanding how the Khavinson research tradition sits within the broader landscape of cardiovascular and longevity research can be a complex area to navigate.
Schedule a consultation with a peptide therapy expert
Frequently Asked Questions (FAQs)
What is a heart bioregulator?
A heart bioregulator is a short peptide complex derived from cardiac tissue and studied for its effects on cardiomyocyte (heart muscle cell) biology and cardiac gene expression. Within the Khavinson bioregulator model, these compounds are proposed to interact with chromatin in cardiac cells and modulate the expression of genes relevant to heart muscle function and maintenance. Chelohart (A-14) is the primary heart bioregulator within the Khavinson Cytomax range.
How do bioregulators differ from peptides?
Most research peptides work through receptor-mediated signalling pathways, where a peptide binds to a receptor on the cell surface and triggers a downstream biological response. Bioregulators, within the Khavinson model, are proposed to work differently, entering the cell nucleus and interacting directly with chromatin to modulate gene expression. This gene-regulatory mechanism, if validated, would represent a fundamentally distinct pharmacological approach to tissue-specific biological regulation.
Who developed the bioregulator research programme?
The bioregulator research programme was developed by Professor Vladimir Khavinson and his team at the St. Petersburg Institute of Bioregulation and Gerontology. The research began in the 1970s within the Soviet military medical system and expanded over subsequent decades into a broad programme of organ-specific peptide bioregulator research. Professor Khavinson has published extensively on the subject and currently serves as President of the European Academy of Gerontology and Geriatrics.
Why is Chelohart an oral capsule rather than an injection?
Chelohart and other Cytomax bioregulators are administered orally because the short chain length of the peptide sequences involved (typically two to four amino acids) is proposed to allow absorption through the gastrointestinal tract without the degradation that affects larger peptide molecules. This distinguishes them from many other research peptides, which require subcutaneous or intravenous administration to reach systemic circulation in an active form.
What are cardiomyocytes and why are they relevant to heart bioregulator research?
Cardiomyocytes are the specialised muscle cells that make up the myocardium (the muscular wall of the heart). They are responsible for the contractile function that drives the heartbeat. Unlike most muscle cells in the body, cardiomyocytes have very limited capacity for self-renewal. Research into compounds that may interact with cardiomyocyte gene expression is therefore of significant interest in the context of cardiac ageing, where the functional capacity of these cells declines progressively over time.
Written by Elizabeth Sogeke, BSc Genetics, MPH
Elizabeth is a science and medical writer specialising in peptide science, longevity medicine, mitochondrial health, metabolic optimisation and regenerative health research. With a BSc in Genetics and a Master’s in Public Health, she combines a strong scientific foundation with experience translating complex biomedical research into clear, clinically informed education for the Peptide Therapy and longevity medicine space. Her work is centred on interpreting emerging peptide, metabolic and longevity research with scientific accuracy, clinical awareness and a clear understanding of how these therapies are being discussed and applied in modern health optimisation.